|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah R, Jones E, Vidart V, Kuppen PJ,
Conti JA and Francis NK: Biomarkers for early detection of
colorectal cancer and polyps: Systematic review. Cancer Epidemiol
Biomarkers Prev. 23:1712–1728. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jimenez CR, Knol JC, Meijer GA and
Fijneman RJ: Proteomics of colorectal cancer: Overview of discovery
studies and identification of commonly identified cancer-associated
proteins and candidate CRC serum markers. J Proteomics.
73:1873–1895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren
N, Hu Y, Yi T, Zhao X, Zhou S, et al: MicroRNAs in colorectal
cancer: Small molecules with big functions. Cancer Lett.
360:89–105. 2015. View Article : Google Scholar
|
|
6
|
Yang X, Zhong J, Ji Y, Li J, Jian Y, Zhang
J and Yang W: The expression and clinical significance of microRNAs
in colorectal cancer detecting. Tumour Biol. 36:2675–2684. 2015.
View Article : Google Scholar
|
|
7
|
Amankwatia EB, Chakravarty P, Carey FA,
Weidlich S, Steele RJ, Munro AJ, Wolf CR and Smith G: MicroRNA-224
is associated with colorectal cancer progression and response to
5-fluorouracil-based chemotherapy by KRAS-dependent and
-independent mechanisms. Br J Cancer. 112:1480–1490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taniguchi K, Sugito N, Kumazaki M,
Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama
K, et al: MicroRNA-124 inhibits cancer cell growth through
PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett.
363:17–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Huang SK, Zhao M, Yang M, Zhong
JL, Gu YY, Peng H, Che YQ and Huang CZ: Identification of a
circulating microRNA signature for colorectal cancer detection.
PLoS One. 9:e874512014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng W, Tu Y, Zhu Y, Wang Z, Li C, Lao L
and Wu G: Predictive power of circulating miRNAs in detecting
colorectal cancer. Tumour Biol. 36:2559–2567. 2015. View Article : Google Scholar
|
|
11
|
Vaish V, Khare T, Verma M and Khare S:
Epigenetic therapy for colorectal cancer. Methods Mol Biol.
1238:771–782. 2015. View Article : Google Scholar
|
|
12
|
Dassow H and Aigner A: MicroRNAs (miRNAs)
in colorectal cancer: From aberrant expression towards therapy.
Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI
|
|
13
|
Ma X, Becker Buscaglia LE, Barker JR and
Li Y: MicroRNAs in NF-kappaB signaling. J Mol Cell Biol. 3:159–166.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun YC, Wang J, Guo CC, Sai K, Wang J,
Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: MiR-181b
sensitizes glioma cells to teniposide by targeting MDM2. BMC
Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bovell LC, Shanmugam C, Putcha BD,
Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE and Manne U: The
prognostic value of microRNAs varies with patient race/ethnicity
and stage of colorectal cancer. Clin Cancer Res. 19:3955–3965.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk
ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN
and CYLD are part of the epigenetic switch linking inflammation to
cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakajima G, Hayashi K, Xi Y, Kudo K,
Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs
hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to
S-1 in Colon Cancer. Cancer Genomics Proteomics. 3:317–324.
2006.
|
|
18
|
Xi Y, Formentini A, Chien M, Weir DB,
Russo JJ and Ju J, Kornmann M and Ju J: Prognostic values of
microRNAs in colorectal cancer. Biomark Insights. 2:113–121.
2006.
|
|
19
|
Xu R, Ma N, Wang F, Ma L, Chen R, Chen R,
Kebinu M, Ma L, Han Z, Ayixiamu, et al: Results of a randomized and
controlled clinical trial evaluating the efficacy and safety of
combination therapy with Endostar and S-1 combined with oxaliplatin
in advanced gastric cancer. Onco Targets Ther. 6:925–929.
2013.PubMed/NCBI
|
|
20
|
Watanabe K, Kawahara H, Enomoto H, Toyama
Y, Akiba T and Yanaga K: Feasibility study of oxaliplatin with oral
S-1 or capecitabine as first-line therapy for patients with
metastases from colorectal cancer. Anticancer Res. 33:4029–4032.
2013.PubMed/NCBI
|
|
21
|
Jordà M and Peinado MA: Methods for DNA
methylation analysis and applications in colon cancer. Mutat Res.
693:84–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gyparaki MT, Basdra EK and Papavassiliou
AG: DNA methylation biomarkers as diagnostic and prognostic tools
in colorectal cancer. J Mol Med Berl. 91:1249–1256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Motoyama K, Inoue H, Takatsuno Y, Tanaka
F, Mimori K, Uetake H, Sugihara K and Mori M: Over- and
under-expressed microRNAs in human colorectal cancer. Int J Oncol.
34:1069–1075. 2009.PubMed/NCBI
|
|
24
|
Kaur S, Lotsari JE, Al-Sohaily S,
Warusavitarne J, Kohonen-Corish MR and Peltomäki P: Identification
of subgroup-specific miRNA patterns by epigenetic profiling of
sporadic and Lynch syndrome-associated colorectal and endometrial
carcinoma. Clin Epigenetics. 7:202015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Fu J, Jiang M, Zhang X, Cheng L,
Xu X, Fan Z, Zhang J, Ye Q and Song H: MiR-410 is overexpressed in
liver and colorectal tumors and enhances tumor cell growth by
silencing FHL1 via a direct/indirect mechanism. PLoS One.
9:e1087082014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Slattery ML, Wolff E, Hoffman MD, Pellatt
DF, Milash B and Wolff RK: MicroRNAs and colon and rectal cancer:
Differential expression by tumor location and subtype. Genes
Chromosomes Cancer. 50:196–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peterson SM, Thompson JA, Ufkin ML,
Sathyanarayana P, Liaw L and Congdon CB: Common features of
microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vlachos IS and Hatzigeorgiou AG: Online
resources for miRNA analysis. Clin Biochem. 46:879–900. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fernandes MS, Carneiro F, Oliveira C and
Seruca R: Colorectal cancer and RASSF family - a special emphasis
on RASSF1A. Int J Cancer. 132:251–258. 2013. View Article : Google Scholar
|
|
30
|
Richter AM, Pfeifer GP and Dammann RH: The
RASSF proteins in cancer; from epigenetic silencing to functional
characterization. Biochim Biophys Acta. 1796:114–128.
2009.PubMed/NCBI
|
|
31
|
Volodko N, Gordon M, Salla M, Ghazaleh HA
and Baksh S: RASSF tumor suppressor gene family: Biological
functions and regulation. FEBS Lett. 588:2671–2684. 2014.
View Article : Google Scholar : PubMed/NCBI
|
